Source: European Medicines Agency (EU) Revision Year: 2026 Publisher: Sanofi Winthrop Industrie, 82 Avenue Raspail, 94250 Gentilly, France
REZUROCK 200 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Pale yellow to yellow, oval shaped tablet, with "KDM" on one side and "200" on the other side, with dimensions of 7.4 x 14.8 mm. |
Each film-coated tablet contains belumosudil mesylate equivalent to 200 mg belumosudil.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Belumosudil is a selective Rho-associated, coiled-coil containing protein kinase-2 (ROCK2) inhibitor that mediates signalling in immune cellular function and fibrotic pathways. |
| List of Excipients |
|---|
|
Tablet core: Cellulose, microcrystalline Tablet coating: Polyvinyl alcohol (E1203) |
High-density polyethylene (HDPE) bottle with polypropylene child-resistant closure and a silica gel desiccant.
Pack size: 28 or 30 film-coated tablets.
Not all pack sizes may be marketed.
Sanofi Winthrop Industrie, 82 Avenue Raspail, 94250 Gentilly, France
EU/1/26/2015/001
EU/1/26/2015/002
| Drug | Countries | |
|---|---|---|
| REZUROCK | Austria, Canada, Estonia, Lithuania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.